Eagle Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$85.9M	Buy	309,589 +63,385	+26%	+$16.5M	0.44%	84
2024 Q2	$59.9M	Sell	246,204 -12,044	-5%	-$1.9M	0.32%	111
2024 Q1	$39.6M	Sell	258,248 -4,617	-2%	-$770K	0.2%	142
2023 Q4	$50.3M	Buy	262,865 +185	+0.1%	+$31.5K	0.27%	125
2023 Q3	$46.5M	Buy	262,680 +3,725	+1%	+$711K	0.28%	125
2023 Q2	$49.2M	Sell	258,955 -4,493	-2%	-$891K	0.27%	123
2023 Q1	$52.8M	Sell	263,448 -225	-0.1%	-$47.3K	0.31%	111
2022 Q4	$61.6M	Buy	263,673 +153	+0.1%	+$32.6K	0.38%	102
2022 Q3	$52.7M	Buy	263,520 +2,217	+0.8%	+$423K	0.34%	104
2022 Q2	$38.1M	Buy	261,303 +5,366	+2%	+$761K	0.24%	138
2022 Q1	$41.8M	Buy	255,937 +607	+0.2%	+$92.5K	0.21%	144
2021 Q4	$43.7M	Buy	255,330 +1,549	+0.6%	+$288K	0.19%	156
2021 Q3	$47.9M	Sell	253,781 -2,128	-0.8%	-$399K	0.22%	158
2021 Q2	$43.4M	Sell	255,909 -249	-0.1%	-$36.5K	0.19%	166
2021 Q1	$36.3M	Buy	256,158 +14,078	+6%	+$2.12M	0.16%	190
2020 Q4	$31.5M	Sell	242,080 -19,794	-8%	-$2.64M	0.18%	182
2020 Q3	$38M	Buy	261,874 +54	+0%	+$7.67K	0.2%	175
2020 Q2	$38.7M	Buy	+261,820	New	+$35.3M	0.22%	157
2013 Q4	–	Sell	-96,415	Closed	-$6.18M	–	616
2013 Q3	$6.18M	Buy	+96,415	New	+$4.81M	0.03%	448